Hemostemix Inc. (CVE:HEM – Get Free Report) shares reached a new 52-week low during trading on Tuesday . The company traded as low as C$0.05 and last traded at C$0.04, with a volume of 29000 shares. The stock had previously closed at C$0.06.
Hemostemix Stock Down 18.2%
The company has a debt-to-equity ratio of -66.09, a current ratio of 0.24 and a quick ratio of 0.48. The firm has a market capitalization of C$9.22 million, a price-to-earnings ratio of -2.25 and a beta of 0.21. The firm’s 50-day moving average price is C$0.06 and its 200 day moving average price is C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Read More
- Five stocks we like better than Hemostemix
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
- Abivax: Wall Street Catches Up to the Data
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
